WHO Immunological Basis for Immunization Series

Module 3: Tetanus Update 2018

Immunization, Vaccines and Biologicals



World Health Organization

The immunological basis for immunization series: module 3: tetanus (Immunological basis for immunization series ; module 3)

ISBN 978-92-4-151361-6

© World Health Organization 2018

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <u>https://creativecommons.org/licenses/by-nc-sa/3.0/igo</u>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. The immunological basis for immunization series: module 3: tetanus. Geneva: World Health Organization; 2018 (Immunological basis for immunization series; module 3). Licence: <u>CC BY-NC-SA 3.0 IGO</u>.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see <u>http://apps.who.int/bookorders</u>. To submit requests for commercial use and queries on rights and licensing, see <u>http://www.who.int/about/licensing</u>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

WHO Immunological Basis for Immunization Series

Module 3: Tetanus Update 2018

Immunization, Vaccines and Biologicals



Contents

Abi	brevia	tions and acronyms	iv	
Pre	face		vi	
Ack	enowl	edgements	vii	
1.	Teta	nus	1	
	1.1	Tetanus toxin	1	
2.	Tetanus toxoid and the nature of immunity against tetanus			
	2.1	Tetanus toxoid vaccine	2	
	2.2	Ietanus toxoid-induced immunity	3	
3.	Tech	niques to measure antibody response	4	
	3.1	Neutralization test in vivo	4	
	3.2 3.3	In vitro techniques	4	
4.	"Pro	tective level" of tetanus antibodies		
5.	Deve	elopment of immunity following vaccination	.14	
	5.1	Immune response to vaccination	14	
	5.2	Duration of immunity following various immunization schedules	16	
	5.3 5.4	Serological surveillance of tetanus toxoid immunity Factors influencing the immune response to tetanus toxoid	20 23	
6.	Place	ental passage of tetanus antitoxin	24	
	6.1	The placenta as a selective organ	24	
	6.2	Influence of interval between TT doses and between the last dose	25	
	63	Eactors influencing the placental transfer of antitoxin	25	
	6.4	Interference between passive antibodies and the development		
		of active immunity to tetanus	27	
	6.5	Effect of maternal tetanus antibodies on infants' response to		
		polysaccharide vaccines conjugated to tetanus toxoid	28	
7.	Effec	tiveness of tetanus toxoid	29	
	7.1	How effective is tetanus toxoid?	29	
	7.2	Reported "failures" of tetanus toxoid immunization	30	
8.	Safety of tetanus toxoid			
9.	Combination vaccines and concomitant vaccine use			
10. Implications for immunization programmes				
References				

Abbreviations and acronyms

ACIP	Advisory Committee on Immunization Practices
ADEM	acute disseminated encephalomyelitis
AEFI	adverse events following immunization
AIDS	acquired immunodeficiency syndrome
CDC	Centers for Disease Control and Prevention (USA)
CIDP	chronic inflammatory disseminated polyneuropathy
Da	Dalton (mass spectrometry)
DTaP	DT-acellular pertussis vaccine
DTP	diphtheria-tetanus-pertussis vaccine
DT	diphtheria-tetanus vaccine for children
EPI	Expanded Programme on Immunization
ELISA	enzyme-linked immunosorbent assay
GBS	Guillain-Barré Syndrome
HA	passive haemagglutination (test)
Hib	Haemophilus influenzae type b
HIV	human immunodeficiency virus
Ig	immunoglobulin
IgG	immunoglobulin G
IgM	immunoglobulin M
IOM	Institute of Medicine (USA)
ITP	immune thrombocytopenic purpura
IU	international units
kg	kilogram
LF	limits of flocculation
mL	millilitre
MNTE	maternal and neonatal tetanus elimination
MNT	Maternal and Neonatal Tetanus

NA	neutralization assay
ng	nanogram
OMS	opsoclonus myoclonus syndrome
PRP	polyribosylribitol phosphate
RIA	radioimmunoassay
RSV	respiratory syncytial virus
SIA	supplementary immunization activities
SIDS	sudden infant death syndrome
Td	preparation of diphtheria and tetanus toxoid with a low amount of diphtheria toxoid, for adolescents and adults
TdaP	preparation of diphtheria, tetanus toxoid and acellular pertussis with a low amount of diphtheria toxoid, for adolescents and adults
ToBI	toxin binding inhibition test
TT	tetanus toxoid
TTCV	tetanus toxoid-containing vaccine
UNICEF	United Nations Children's Fund
VMMC	voluntary male medical circumcision
WHO	World Health Organization

Preface

This module is part of the WHO series The immunological basis for immunization, which was initially developed in 1993 as a set of eight modules, comprising one module on general immunology and seven modules each devoted to one of the vaccines recommended for the Expanded Programme on Immunization – i.e. vaccines against diphtheria, measles, pertussis, polio, tetanus, tuberculosis and yellow fever. Since then, this series has been updated and extended to include other vaccines of international importance. The main purpose of the modules is to provide national immunization managers and vaccination professionals with an overview of the scientific basis of vaccination against a range of important infectious diseases. The modules developed since 1993 continue to be vaccine-specific, reflecting the biological differences in immune responses to the individual pathogens and the differing strategies employed to create the best possible level of protection that can be provided by vaccination. The modules also serve as a record of the immunological basis for the WHO recommendations on vaccine use, as published in the WHO vaccine position papers.¹

¹ See: <u>http://www.who.int/immunization/documents/positionpapers_intro/en/index.html</u>, accessed 31 July 2018.

Acknowledgements

The preparation of this publication was coordinated by the Director's office of the WHO Department of Immunization, Vaccines, and Biologicals. WHO thanks the donors whose unspecified financial support has made the production of this document possible.

This module was updated for WHO by Nicole E. Basta, Assistant Professor, Division of Epidemiology and Community Health, University of Minnesota, USA; Ray Borrow, Vaccine Evaluation Unit, Public Health England, Manchester, United Kingdom and Elizabeth Miller, Immunisation Department, Public Health England, London, United Kingdom. No conflict of interest was declared.²

WHO thanks those who provided expert and technical reviews for the initial preparation of the module and the 2018 update: Thomas Cherian, WHO; Kyla Hayford, Division: Global Disease Epidemiology and Control, Johns Hopkins Bloomberg School of Public Health; Dianliang Lei, WHO; Elisabeth Raquel Krow-Lucal U.S. Centers for Disease Control and Prevention; Heather Scobie, U.S. Centers for Disease Control and Prevention.

预览已结束,完整报告链接和二维码如下:



https://www.yunbaogao.cn/report/index/report?reportId=5 25573